out of 100,000 people have PWS
assays available for clinical studies
The metabolic syndrome includes diseases such as diabetes, obesity, hypertension but also rare diseases like the Prader Willi syndrome. These diseases affect all classes and profiles of the world's population. To fight against this plague, two remedies: to change our way of life and find the right treatments.
Using biomarkers to fight obesity
Over the past 20 years, the number of obese people has tripled in developed countries to reach 312 million. 1.1 billion adults are overweight. This global plague can be undermined by the early diagnosis of good biomarkers (a measurable biological indicator linked to a normal biological pathological process or to a response to an exposure) of these diseases. Once these biomarkers are identified and analyzed, laboratories can develop the treatment.
Dosing the hunger hormone: Ghrelin
With more than 30 years of experience in the development of biomarker assay kits, Bertin Pharma collaborated with Alize Pharma to develop the Ghrelin assay, commonly known as the “hunger hormone”. This indicator, once quantified, evaluates the efficacy and toxicity of Alize Pharma’s drug candidate, “AZP-531”.
Bertin Pharma has therefore developed analytical methods for each of the key stages in the development of this drug: from screening cellular models to analyzing preclinical and clinical studies.
Treatment for the Prader Willi syndrome
Bertin Pharma participated in the accelerated development of a treatment for people with Prader Willi syndrome.
This genetic syndrome is characterized at birth by decreased muscle tone (hypotonia) associated with decreased calorie expenditure and excessive intake of food (hyperphagia). Unchecked, this disease causes serious obesity that can lead to death.
To date, compound AZP 531 is undergoing Phase I and II clinical studies.